New Drug Approvals in China in 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse…
Address: Ocean Towers 15th Floor, 550 Yanan East Road, Shanghai ,China
Tel: +86 21 5306 0001
Web: http://www.zuelligpharma.com/
Zuellig Pharma was first established in Asia over 60 years ago and has become the leading healthcare distribution solution specialist in 15 countries and regions in Asia. Zuellig Pharma combines regional market expertise with constantly evolving quality services, IT systems, facilities and management in order to create enduring market partnerships based on trust, open communication, responsiveness, vision and top results.
In the past six decades, Zuellig Pharma has built up extensive experience in Asia Pacific, meeting the ever-changing needs of the market place through continuous innovation, efficiency and forward looking management. By combining extensive local market expertise with global vision and the latest technological developments Zuellig Pharma provides dedicated, cutting-edge distribution solutions to the healthcare industry. Zuellig Pharma’s state-of-the art facilities operate in strict accordance with rigorous quality management standards and set industry benchmarks for excellence.
Distribution services
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six…
The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how the country’s online healthcare industry is booming in the wake of the pandemic, and news that…
The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement,…
PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical libraries (DEL) and their multipronged business strategy. Established…
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to…
While cell and gene therapies are all the rage now, a little known fact is that the world’s first approved gene therapy actually came from a Chinese company – in…
See our Cookie Privacy Policy Here
